Is the new NICE appraisal process for oncology indications too positive in its assessment of cancer drugs in England?

///Is the new NICE appraisal process for oncology indications too positive in its assessment of cancer drugs in England?
Is the new NICE appraisal process for oncology indications too positive in its assessment of cancer drugs in England?2019-01-18T09:19:20+00:00

Project Description

Since 29 July 2016, the NICE appraisal process for oncology indications in England has been modified to allow one of three outcomes; recommended for routine use, not recommended, or recommended within the Cancer Drugs Fund (CDF) managed access scheme. This study investigates the outcomes of NICE appraisals for new cancer drugs assessed via the modified process.

Read our findings here…… (Is the new NICE appraisal process too positive?)